摘要
在美国吗,肺癌导致死亡的主要原因,非小细胞肺癌是其最常见的类型。在过去的几十年中,手术和全身治疗非小细胞肺癌取得了巨大进展,但晚期疾病的预后仍然较差。然而,治疗非小细胞肺癌新的研究是探索使用靶向治疗。间变性淋巴瘤激酶(ALK)参与正常哺乳动物中枢神经系统发育。一种涉及ALK的融合基因以及棘皮动物微管相关蛋白4(EML4)基因与5%的NSCLCs有关,并与其他致癌基因相互排斥。抗ALK靶向治疗重排是一种相对较新的治疗方式,其旨在改善晚期癌症患者的预后。两类药物Crizotinib 和 Ceritinib已经得到了FDA的批准。以及许多其他ALK抑制剂目前正处于临床试验研究阶段。本文对ALK抑制剂治疗NSCLCs进行了总结,并对将来的研究方向和挑战提出了看法。
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
Current Drug Targets
Title:Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Volume: 17 Issue: 6
Author(s): David M. Straughan, Sad C. Azoury and Vivek Shukla
Affiliation:
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
摘要: Lung cancer is the leading cause of cancer death among both sexes in the United States and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Over the last several decades, there have been many advances in both surgical approaches and systemic therapies for the treatment of NSCLC, but the prognosis for advanced disease remains poor. New research, however, is exploring the use of targeted therapies for the treatment of NSCLC. The anaplastic lymphoma kinase (ALK) is involved in normal mammalian central nervous system development. A novel fusion gene involving ALK and the echinoderm microtubule-associated protein-like 4 (EML4) gene has been associated with approximately 5% of NSCLCs and is mutually exclusive of other oncogenic driver mutations. Targeted therapies against this ALK rearrangement are a relatively new treatment modality that aims to improve the prognosis of patients with late-stage disease. Two such drugs have Food and Drug Administration (FDA) approval currently: Crizotinib and Ceritinib. Many other ALK inhibitors are currently being studied in clinical trials as well. The authors aim to provide a comprehensive review of ALK inhibitors for use in NSCLC as well as the future directions and challenges to developing these targeted therapies.
Export Options
About this article
Cite this article as:
David M. Straughan, Sad C. Azoury and Vivek Shukla , Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1573399811666150615144336
DOI https://dx.doi.org/10.2174/1573399811666150615144336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Activation of Large Form Galanin-LI by Extracellular Processing in Small Cell Lung Carcinoma Tissue
Protein & Peptide Letters Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design SYNTHESIS AND APPLICATIONS OF Fe3O4/SiO2 CORE-SHELL MATERIALS
Current Pharmaceutical Design On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism Metal-Based Antioxidants - Potential Therapeutic Candidates for Prevention the Oxidative Stress - Related Carcinogenesis: Mini-Review
Current Topics in Medicinal Chemistry The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Gender Disparity in Pediatric Diseases
Current Molecular Medicine Subject Index To Volume 7
Current Drug Metabolism “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Assessment of Airway Inflammation by Exhaled Breath Condensate and Impedance Due to Gastroesophageal Reflux Disease (GERD)
Inflammation & Allergy - Drug Targets (Discontinued) DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology A Review of Aberrant DNA Methylation and Epigenetic Agents Targeting DNA Methyltransferases in Endometriosis
Current Drug Targets Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries
Current Cancer Therapy Reviews Engineered Magnetic Core-Shell Structures
Current Pharmaceutical Design